Expanded Access to Venetoclax

Last updated: January 29, 2026
Sponsor: AbbVie
Overall Status: Planned

Phase

N/A

Condition

Multiple Myeloma

Cancer/tumors

Lymphoproliferative Disorders

Treatment

Venetoclax

Clinical Study ID

NCT03123029
C16-431
C20-485
C19-920
  • All Genders

Study Summary

This is an expanded access program (EAP) for eligible participants. This program is designed to provide access to Venetoclax prior to approval by the local regulatory agency. Availability will depend on territory eligibility. A medical doctor must decide whether the potential benefit outweighs the risk of receiving an investigational therapy based on the individual patient's medical history and program eligibility criteria.

Eligibility Criteria

Inclusion

Exclusion Criteria:

  • There are other suitable treatment options.

  • The participant qualifies for ongoing clinical trials.

Study Design

Treatment Group(s): 1
Primary Treatment: Venetoclax
Phase:
Study Start date:
Estimated Completion Date: